{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:13:23Z","timestamp":1793578403091,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24832-9","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:37:47Z","timestamp":1763635067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["LDL cholesterol and clinical outcomes in heart failure with reduced ejection fraction a competing risk analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"32","key":"24832_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 38 (32), 2459\u20132472. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144 (2017).","journal-title":"Eur. Heart J."},{"issue":"4","key":"24832_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/svn-2021-001317","volume":"7","author":"Y Pan","year":"2022","unstructured":"Pan, Y. et al. LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA. Stroke Vasc Neurol. 7 (4), 276\u2013284. https:\/\/doi.org\/10.1136\/svn-2021-001317 (2022).","journal-title":"Stroke Vasc Neurol."},{"issue":"25","key":"24832_CR3","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth, G. A. et al. Global burden of cardiovascular diseases and risk Factors, 1990\u20132019: update from the GBD 2019 study. J. Am. Coll. Cardiol. 76 (25), 2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"24832_CR4","doi-asserted-by":"publisher","unstructured":"Johannesen, C. D. L., Langsted, A., Mortensen, M. B. & Nordestgaard, B. G. Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study (published correction appears in BMJ. ;372:n422. doi: 10.1136\/bmj.n422.). BMJ. 2020;371:m4266. Published 2020 Dec 8. (2021). https:\/\/doi.org\/10.1136\/bmj.m4266","DOI":"10.1136\/bmj.m4266"},{"issue":"16","key":"24832_CR5","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/eurheartj\/ehae868","volume":"46","author":"BJ van Essen","year":"2025","unstructured":"van Essen, B. J. et al. Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years. Eur. Heart J. 46 (16), 1528\u20131536. https:\/\/doi.org\/10.1093\/eurheartj\/ehae868 (2025).","journal-title":"Eur. Heart J."},{"issue":"11","key":"24832_CR6","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.jacc.2003.07.016","volume":"42","author":"M Rauchhaus","year":"2003","unstructured":"Rauchhaus, M. et al. The relationship between cholesterol and survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 42 (11), 1933\u20131940. https:\/\/doi.org\/10.1016\/j.jacc.2003.07.016 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"24832_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2003.11.039","volume":"43","author":"K Kalantar-Zadeh","year":"2004","unstructured":"Kalantar-Zadeh, K., Block, G., Horwich, T. & Fonarow, G. C. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J. Am. Coll. Cardiol. 43 (8), 1439\u20131444. https:\/\/doi.org\/10.1016\/j.jacc.2003.11.039 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"24832_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.108.825059","volume":"2","author":"G G\u00fcder","year":"2009","unstructured":"G\u00fcder, G. et al. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ. Heart Fail. 2 (6), 563\u2013571. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.108.825059 (2009).","journal-title":"Circ. Heart Fail."},{"issue":"5","key":"24832_CR9","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3390\/nu13051669","volume":"13","author":"M Czapla","year":"2021","unstructured":"Czapla, M., Ju\u00e1rez-Vela, R., \u0141okie\u0107, K. & Karniej, P. The association between nutritional status and In-Hospital mortality among patients with heart Failure-A result of the retrospective nutritional status heart study 2 (NSHS2). Nutrients 13 (5), 1669. https:\/\/doi.org\/10.3390\/nu13051669 (2021). Published 2021 May 14.","journal-title":"Nutrients"},{"issue":"4","key":"24832_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.repc.2025.03.002","volume":"44","author":"R Gomes","year":"2025","unstructured":"Gomes, R. & Aguiar, C. Revisiting the cholesterol paradox in heart failure. Is LDL-cholesterol a target of treatment or a marker of risk? Rev. Port Cardiol. 44 (4), 201\u2013203. https:\/\/doi.org\/10.1016\/j.repc.2025.03.002 (2025).","journal-title":"Rev. Port Cardiol."},{"issue":"4","key":"24832_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ejhf.247","volume":"17","author":"MJ Feinstein","year":"2015","unstructured":"Feinstein, M. J. et al. Do Statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur. J. Heart Fail. 17 (4), 434\u2013441. https:\/\/doi.org\/10.1002\/ejhf.247 (2015).","journal-title":"Eur. J. Heart Fail."},{"issue":"14","key":"24832_CR12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.2009.454","volume":"301","author":"CM O\u2019Connor","year":"2009","unstructured":"O\u2019Connor, C. M. et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301 (14), 1439\u20131450. https:\/\/doi.org\/10.1001\/jama.2009.454 (2009).","journal-title":"JAMA"},{"issue":"15","key":"24832_CR13","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","volume":"319","author":"EP Navarese","year":"2018","unstructured":"Navarese, E. P. et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and Meta-analysis. JAMA 319 (15), 1566\u20131579. https:\/\/doi.org\/10.1001\/jama.2018.2525 (2018).","journal-title":"JAMA"},{"key":"24832_CR14","doi-asserted-by":"publisher","unstructured":"Gouveia, R. et al. Lower low density lipoprotein cholesterol associates to higher mortality in non-diabetic heart failure patients. Int J Cardiol Cardiovasc Risk Prev. ;18:200197. Published 2023 Jul 16. (2023). https:\/\/doi.org\/10.1016\/j.ijcrp.2023.200197","DOI":"10.1016\/j.ijcrp.2023.200197"},{"issue":"1","key":"24832_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41 (1), 111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455 (2020).","journal-title":"Eur. Heart J."},{"key":"24832_CR16","doi-asserted-by":"publisher","unstructured":"Mach, F. et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Atherosclerosis Published Online August. 28 https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120479 (2025).","DOI":"10.1016\/j.atherosclerosis.2025.120479"},{"issue":"25","key":"24832_CR17","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl. J. Med. 372 (25), 2387\u20132397. https:\/\/doi.org\/10.1056\/NEJMoa1410489 (2015).","journal-title":"N Engl. J. Med."},{"issue":"18","key":"24832_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl. J. Med. 376 (18), 1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664 (2017).","journal-title":"N Engl. J. Med."},{"issue":"22","key":"24832_CR19","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl. J. Med. 379 (22), 2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174 (2018).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"24832_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.amjcard.2009.08.660","volume":"105","author":"G Charach","year":"2010","unstructured":"Charach, G. et al. Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure. Am. J. Cardiol. 105 (1), 100\u2013104. https:\/\/doi.org\/10.1016\/j.amjcard.2009.08.660 (2010).","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"24832_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.repc.2024.09.004","volume":"44","author":"J Brito","year":"2025","unstructured":"Brito, J. et al. Association of LDL-cholesterol with prognosis in patients admitted for acutely decompensated heart failure. Rev. Port Cardiol. 44 (4), 191\u2013200. https:\/\/doi.org\/10.1016\/j.repc.2024.09.004 (2025).","journal-title":"Rev. Port Cardiol."},{"issue":"22","key":"24832_CR22","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus, J. et al. Rosuvastatin in older patients with systolic heart failure. N Engl. J. Med. 357 (22), 2248\u20132261. https:\/\/doi.org\/10.1056\/NEJMoa0706201 (2007).","journal-title":"N Engl. J. Med."},{"issue":"9645","key":"24832_CR23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi, L. et al. Effect of Rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (9645), 1231\u20131239. https:\/\/doi.org\/10.1016\/S0140-6736(08)61240-4 (2008).","journal-title":"Lancet"},{"issue":"16","key":"24832_CR24","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab804","volume":"43","author":"HD White","year":"2022","unstructured":"White, H. D. et al. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur. Heart J. 43 (16), 1554\u20131565. https:\/\/doi.org\/10.1093\/eurheartj\/ehab804 (2022).","journal-title":"Eur. Heart J."},{"issue":"1","key":"24832_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijcard.2007.05.026","volume":"129","author":"JP Ara\u00fajo","year":"2008","unstructured":"Ara\u00fajo, J. P. et al. Cholesterol\u2013a marker of nutritional status in mild to moderate heart failure. Int. J. Cardiol. 129 (1), 65\u201368. https:\/\/doi.org\/10.1016\/j.ijcard.2007.05.026 (2008).","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"24832_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1054\/jcaf.2002.0804216","volume":"8","author":"TB Horwich","year":"2002","unstructured":"Horwich, T. B., Hamilton, M. A., Maclellan, W. R. & Fonarow, G. C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card Fail. 8 (4), 216\u2013224. https:\/\/doi.org\/10.1054\/jcaf.2002.0804216 (2002).","journal-title":"J. Card Fail."},{"issue":"15","key":"24832_CR27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue, M. L. et al. Long-Term Evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 146 (15), 1109\u20131119. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620 (2022).","journal-title":"Circulation"},{"issue":"9753","key":"24832_CR28","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT)","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) et al. Efficacy and safety of more intensive Lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (9753), 1670\u20131681. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5 (2010).","journal-title":"Lancet"},{"issue":"12","key":"24832_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","volume":"11","author":"KA Krychtiuk","year":"2022","unstructured":"Krychtiuk, K. A. et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the association for acute cardiovascular care (ACVC), in collaboration with the European association of preventive cardiology (EAPC) and the European society of cardiology working group on cardiovascular pharmacotherapy. Eur. Heart J. Acute Cardiovasc. Care. 11 (12), 939\u2013949. https:\/\/doi.org\/10.1093\/ehjacc\/zuac123 (2022).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"16","key":"24832_CR30","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","volume":"147","author":"P Gaba","year":"2023","unstructured":"Gaba, P. et al. Association between achieved Low-Density lipoprotein cholesterol levels and Long-Term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation 147 (16), 1192\u20131203. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.063399 (2023).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24832-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:37:47Z","timestamp":1763635067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24832-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24832"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24832-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40939"}}